A randomized, double- blind, placebo- controlled study of the lowest effective dose of drospirenone with 17 beta- estradiol for moderate to severe vasomotor symptoms in postmenopausal women Article

sustainable development goals

authors

publication date

  • March 1, 2014

webpage

published in

keywords

  • 17-Estradiol
  • Drospirenone
  • Hot flushes
  • Postmenopausal women
  • Vasomotor symptoms

start page

  • 227

end page

  • 235

volume

  • 21

issue

  • 3